
Operations Office

Telephone (507) 266-3549



Date: November 21, 2003

To: Primary Clinical Research Associates

From: Lori K. Kelly
Protocol Development Coordinator

Re: N0272, Phase II Trial of STI-571 in Treatment of Recurrent
Oligodendroglioma and Mixed Oligoastrocytoma

Attached is a revised eligibility checklist. The “Required Characteristic” for ≥ 4 weeks from other chemotherapy prior to study entry has been revised to include “vs. not applicable ____.”

Also attached is a revised abstract. On page 2 of the schema section of the abstract, the IMATINIB DOSE section, Arm B, shows the dose as 600 mg po bid daily. ***The dose should actually be 600 mg po daily.***

Please replace your current versions of the eligibility checklist, abstract, and forms packet cover sheet with these revised versions.

Thank you.

Enclosure